KRAS and non-small cell lung carcinoma: An ongoing phase 1–2 study of MRTX849 (adagrasib) in KRAS G12C mutant cancers has shown an objective response rate of 45% in NSCLC patients in a KRYSTAL-1 trial, with a DCR of 96% [14].